Foxx Life Sciences Adds New Asia Headquarters in India
Foxx Life Sciences announce new Asia headquarters in India.
In a recent press release (1), Foxx Life Sciences announced that their custom single-use systems (SUS) company will be opening their new international Asia headquarters in Medchal, Hyderabad, India. With this new location, Foxx will bring continued expansion of biopharmaceutical manufacturing to the region.
"Foxx is proud to expand in Asia to offer innovative products to the Indian and Asian markets,” said Vikram Mahapatra, vice president of Foxx Life Sciences (1). “We are happy to be committed to providing our customers with high-quality products with exceptional global customer service.”
Foxx Life Sciences will maintain its initiative to invest in the strong demand growth forecasted in the India and Asia markets for Foxx Custom (SUT), which is specifically designed to support biopharmaceutical and bioprocess companies.
Following the addition of Foxx Life Sciences new facility, they launched a new website, https://www.foxxlifesciences.in, regarding product knowledge and online purchasing of their products for Asia customers.
"Foxx is recognized as the bridge to India in the USA" stated Thomas Taylor, President and CEO.
The new headquarters will also include warehouse inventory and manufacturing for the Asian-Pacific region.
Reference
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
